CELGENE CORP CELG
March 03, 2019 - 7:32pm EST by
pcm983
2019 2020
Price: 85.96 EPS 10.70 13.00
Shares Out. (in M): 702 P/E 8 6.6
Market Cap (in $M): 60,000 P/FCF n/a n/a
Net Debt (in $M): 14,000 EBIT 0 0
TEV ($): 74,000 TEV/EBIT n/a n/a

Sign up for free guest access to view investment idea with a 45 days delay.

 

Description

The Celgene / Bristol Myers Squibb deal presents an interesting merger arbitrage opportunity. The deal was announced on 1/3/19 and if it goes through CELG shareholders will receive: 1) $50 in cash 2) 1 BMY share 3) 1 CVR related to Celgene's current drug pipeline. 

https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-acquire-celgene-create-premier-innovative

In terms of the CVR, it could ultimately be worth $9, but could also be worth 0 given it is binary: in order for it to pay-out three drugs need to be approved by specific dates - most market participants think this is a combined 55-70% for each one ^ 3 which gets to a compound probabilty of ~20% so around $2-2.50 in expected value. There is some risk on some of the timelines as they are quite close to Celgene management targets so if they are delayed at all or need to be refiled and miss the deadline, the CVR is worthless (i.e., if even one drug misses the relevant date the CVR is a 0).

The deal has had a fairly wide spread for a deal of this nature given concerns someone would go activist on BMY to try to block the deal given BMY's stock dropped ~12% in response to the deal, and so this presented a big risk for the long CELG / short BMY trade. There were rumors for some time that Starboard had taken a position in BMY, but it was not clear they were necessarily against the CELG deal. There were several news articles and an interview with Jeff Smith and David Faber that hinted they might be against the deal.

https://www.youtube.com/watch?v=xHvmL8zNLec

https://www.wsj.com/articles/starboard-value-nominates-five-to-bristol-myers-board-11550683021

 

The WSJ article also noted that Dodge & Cox is potentially against the deal, though noted this does not necessarily mean they would vote against it.

Wednesday afternoon, Wellington which owns 8% of BMY came out against the deal, noting:

 "While Wellington agrees that Bristol-Myers should be active in business development that secures differentiated science and broadens the future revenue base, Wellington does not believe that the Celgene transaction is an attractive path towards accomplishing this goal. Wellington’s conclusion is based upon three tenets: 1) the transaction asks BMY shareholders to accept too much risk and the terms offer BMY shares to CELG shareholders at a price well below implied asset value; 2) execution success could be more difficult to achieve than depicted by Company management; and 3) alternative paths to create value for BMY shareholders could be more attractive."

There is some debate around how big Wellington's actual voting stake is given they noted in their 13D they have voting power over 28.2mm shares vs. their economic stake of 125.7mm shares (2% of shares out and 8% of shares out respectively). The shares that they economically own but do not control the voting for are related to Vanguard mutual funds that Wellington is the investment advisor for. No one knows for sure how these shares will be voted (i.e., if they will vote in-line with other Vanguard or shares, or if Wellington's input will be listened to and they will be voted in-line with Wellington's position).

On Thursday morning, Starboard came out with it's letter stating that they are against the deal, as they feel BMY management has not earned the right to do a bet the farm type deal and they think CELG's patent cliff risk and pipeline risk are not worth the investment. Additionally, they seem to want BMY to put itself up for sale.

https://www.sec.gov/Archives/edgar/data/14272/000092189519000610/ex1todfan14a06297263_022819.pdf

The letter is quite odd given it criticizes BMY management and says they have done a bad job, have positioned the company poorly, etc. and then goes on to say that someone might be interested in buying BMY. If BMY's current strategic positioning is so bad, it seems odd that someone else would be desparate to buy BMY - this would set-up much the same as the CELG deal for whatever company would theoretically try to buy BMY. Also, I think it is interesting to think about the strategy behind why BMY wanted to buy CELG in the first place - it seems likely management recognized its own strategic positioning was in a precarious position so they needed a big strategic deal to address this concern - i.e., in a way they need a deal like this because otherwise their own pipeline / patent cliff situation is quite bad.

The main argument in favor of the deal going through is that a large portion of the shareholder bases of the two company's overlap - ~>40-50% - which means that in theory most of those shareholders should be indifferent or even happy for the two companies to merge as there are a good deal of synergies - i.e., you already own both and want G&A / other costs to be lower in aggregate.

Based on current information, we know that Starboard has 4.4mm (0.3%) shares per their proxy Friday, Dodge & Cox has ~2.6%, Wellington has either 2% or 8% - so in a more conservative scenario that means there is ~11% of BMY shares against the deal if we assume Wellington can vote its entire stake and Dodge & Cox votes against the deal (both of which we don't know for sure). It seems hard for this contingent to be enough to block the deal given the large share overlap mentioned above, and there isn't really anyone with a large enough BMY position to move the needle. The vote will primarily hinge on how ISS / Glass Lewis come out re the deal, and in turn how the likes of Vanguard et al vote. It's important to note that in Vanaguard's proxy voting guidelines, they generally defer to management, and in this case it seems like management can make a very strong case that they need this deal strategically.

One other angle that I think is potentially interesting here - the move by Starboard caused the CELG spread to blow out by ~10 pts on Thursday and there was a lot of turnover both on the BMY and CELG sides - I think this has potentially opened up an opportunity for someone else to come in and buy stakes in both BMY and CELG and publicly support the deal.

In summary, I think the current spread of ~18.7% (using $2.50 value for the CVR) is very attractive and likely to compress significantly as fears over the Starboard activism subside. Whether it will be attractive to hold for the duration of the deal or not will depend on the trading dynamics and newsflow going forward.

Risks:

1) deal being blocked by BMY shareholder vote

2) probably the most important risk is someone bidding for BMY - I don't view this as particularly likely given there are only a handful of companies who can bid and they don't seem interested - and there haven't been any rumors of such interest since the deal was announced - but this is certainly possible and would be problematic from the spread perspective of being long CELG / short BMY

3) usual risks associated with M&A deal closing - i.e., relevant regulatory approvals

4) this has become a bit of a consensus trade - given there are not many large M&A deals out there with relatively large spreads, a lot of arbs have been involved in this trade - that said, positioning is obviously less aggressive given the big move on Thursday

If the deal breaks, CELG probably trades to ~$68-$72 - this is based on a few things, namely the IBB rally YTD of ~20%, due in large part to the massive M&A wave in pharma kicked off by BMY initially, and the $3 per CELG share break fee. Additionally, it's quite possible someone else would be interested in CELG if this deal falls through. In this scenario, I would expect BMY to trade up a bit, but some of this has already started to be priced in given the headlines over the last week - I would think BMY could trade to $55-$56 - which means the total risk / reward of the trade is ~1:1 which seems very attractive.

I do not hold a position with the issuer such as employment, directorship, or consultancy.
I and/or others I advise hold a material investment in the issuer's securities.

Catalyst

Shareholder votes in mid-April - the record date for BMY was Friday, so it's unlikely anyone new can enter the fray from an activism / voting perspective

Deal anticipated closing in Q3 2019

    sort by    

    Description

    The Celgene / Bristol Myers Squibb deal presents an interesting merger arbitrage opportunity. The deal was announced on 1/3/19 and if it goes through CELG shareholders will receive: 1) $50 in cash 2) 1 BMY share 3) 1 CVR related to Celgene's current drug pipeline. 

    https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-acquire-celgene-create-premier-innovative

    In terms of the CVR, it could ultimately be worth $9, but could also be worth 0 given it is binary: in order for it to pay-out three drugs need to be approved by specific dates - most market participants think this is a combined 55-70% for each one ^ 3 which gets to a compound probabilty of ~20% so around $2-2.50 in expected value. There is some risk on some of the timelines as they are quite close to Celgene management targets so if they are delayed at all or need to be refiled and miss the deadline, the CVR is worthless (i.e., if even one drug misses the relevant date the CVR is a 0).

    The deal has had a fairly wide spread for a deal of this nature given concerns someone would go activist on BMY to try to block the deal given BMY's stock dropped ~12% in response to the deal, and so this presented a big risk for the long CELG / short BMY trade. There were rumors for some time that Starboard had taken a position in BMY, but it was not clear they were necessarily against the CELG deal. There were several news articles and an interview with Jeff Smith and David Faber that hinted they might be against the deal.

    https://www.youtube.com/watch?v=xHvmL8zNLec

    https://www.wsj.com/articles/starboard-value-nominates-five-to-bristol-myers-board-11550683021

     

    The WSJ article also noted that Dodge & Cox is potentially against the deal, though noted this does not necessarily mean they would vote against it.

    Wednesday afternoon, Wellington which owns 8% of BMY came out against the deal, noting:

     "While Wellington agrees that Bristol-Myers should be active in business development that secures differentiated science and broadens the future revenue base, Wellington does not believe that the Celgene transaction is an attractive path towards accomplishing this goal. Wellington’s conclusion is based upon three tenets: 1) the transaction asks BMY shareholders to accept too much risk and the terms offer BMY shares to CELG shareholders at a price well below implied asset value; 2) execution success could be more difficult to achieve than depicted by Company management; and 3) alternative paths to create value for BMY shareholders could be more attractive."

    There is some debate around how big Wellington's actual voting stake is given they noted in their 13D they have voting power over 28.2mm shares vs. their economic stake of 125.7mm shares (2% of shares out and 8% of shares out respectively). The shares that they economically own but do not control the voting for are related to Vanguard mutual funds that Wellington is the investment advisor for. No one knows for sure how these shares will be voted (i.e., if they will vote in-line with other Vanguard or shares, or if Wellington's input will be listened to and they will be voted in-line with Wellington's position).

    On Thursday morning, Starboard came out with it's letter stating that they are against the deal, as they feel BMY management has not earned the right to do a bet the farm type deal and they think CELG's patent cliff risk and pipeline risk are not worth the investment. Additionally, they seem to want BMY to put itself up for sale.

    https://www.sec.gov/Archives/edgar/data/14272/000092189519000610/ex1todfan14a06297263_022819.pdf

    The letter is quite odd given it criticizes BMY management and says they have done a bad job, have positioned the company poorly, etc. and then goes on to say that someone might be interested in buying BMY. If BMY's current strategic positioning is so bad, it seems odd that someone else would be desparate to buy BMY - this would set-up much the same as the CELG deal for whatever company would theoretically try to buy BMY. Also, I think it is interesting to think about the strategy behind why BMY wanted to buy CELG in the first place - it seems likely management recognized its own strategic positioning was in a precarious position so they needed a big strategic deal to address this concern - i.e., in a way they need a deal like this because otherwise their own pipeline / patent cliff situation is quite bad.

    The main argument in favor of the deal going through is that a large portion of the shareholder bases of the two company's overlap - ~>40-50% - which means that in theory most of those shareholders should be indifferent or even happy for the two companies to merge as there are a good deal of synergies - i.e., you already own both and want G&A / other costs to be lower in aggregate.

    Based on current information, we know that Starboard has 4.4mm (0.3%) shares per their proxy Friday, Dodge & Cox has ~2.6%, Wellington has either 2% or 8% - so in a more conservative scenario that means there is ~11% of BMY shares against the deal if we assume Wellington can vote its entire stake and Dodge & Cox votes against the deal (both of which we don't know for sure). It seems hard for this contingent to be enough to block the deal given the large share overlap mentioned above, and there isn't really anyone with a large enough BMY position to move the needle. The vote will primarily hinge on how ISS / Glass Lewis come out re the deal, and in turn how the likes of Vanguard et al vote. It's important to note that in Vanaguard's proxy voting guidelines, they generally defer to management, and in this case it seems like management can make a very strong case that they need this deal strategically.

    One other angle that I think is potentially interesting here - the move by Starboard caused the CELG spread to blow out by ~10 pts on Thursday and there was a lot of turnover both on the BMY and CELG sides - I think this has potentially opened up an opportunity for someone else to come in and buy stakes in both BMY and CELG and publicly support the deal.

    In summary, I think the current spread of ~18.7% (using $2.50 value for the CVR) is very attractive and likely to compress significantly as fears over the Starboard activism subside. Whether it will be attractive to hold for the duration of the deal or not will depend on the trading dynamics and newsflow going forward.

    Risks:

    1) deal being blocked by BMY shareholder vote

    2) probably the most important risk is someone bidding for BMY - I don't view this as particularly likely given there are only a handful of companies who can bid and they don't seem interested - and there haven't been any rumors of such interest since the deal was announced - but this is certainly possible and would be problematic from the spread perspective of being long CELG / short BMY

    3) usual risks associated with M&A deal closing - i.e., relevant regulatory approvals

    4) this has become a bit of a consensus trade - given there are not many large M&A deals out there with relatively large spreads, a lot of arbs have been involved in this trade - that said, positioning is obviously less aggressive given the big move on Thursday

    If the deal breaks, CELG probably trades to ~$68-$72 - this is based on a few things, namely the IBB rally YTD of ~20%, due in large part to the massive M&A wave in pharma kicked off by BMY initially, and the $3 per CELG share break fee. Additionally, it's quite possible someone else would be interested in CELG if this deal falls through. In this scenario, I would expect BMY to trade up a bit, but some of this has already started to be priced in given the headlines over the last week - I would think BMY could trade to $55-$56 - which means the total risk / reward of the trade is ~1:1 which seems very attractive.

    I do not hold a position with the issuer such as employment, directorship, or consultancy.
    I and/or others I advise hold a material investment in the issuer's securities.

    Catalyst

    Shareholder votes in mid-April - the record date for BMY was Friday, so it's unlikely anyone new can enter the fray from an activism / voting perspective

    Deal anticipated closing in Q3 2019

    Messages


    SubjectI agree, CELG likely to close
    Entry03/06/2019 12:10 PM
    Membermajic06

    I like this arb a lot at these levels.  I found the BMY presentation today to be compelling and I think it's extremely likely ISS goes along, as the usually do in situations like this. 

    I don't think the vote will even be close. 


    SubjectRe: I agree, CELG likely to close
    Entry03/06/2019 09:56 PM
    MemberMadDog2020

    Anything else that gives you this level of certainty Majic?


    SubjectCELG spread way too wide
    Entry03/12/2019 02:38 PM
    Membermajic06

    Currently 19.5% gross (not annualized) (was 23% or so when I posted below) if you count the CVR as $2.  

    BMY said today they haven't had ANY informal talks with ANYONE looking to acquire them since 2017.   This is important because it means nobody as approached them in the last 10 weeks, even for a chat.  I believe this puts aside any risk someone comes in for BMY before the shareholder vote.

    Additionally, all the large holders ex Wellington also are the largest holders in CELG!  I don't see them voting against their own interests.

    But most importantly, sell siders are getting behind the deal.  I can't see ISS panning a deal that many find attractive.  It isn't some clear cut value destructive deal.  I think it makes sense for BMY.

    The spread should be south of 15% and probably 10% right now going into this vote, given all we know today.   With that said, I'm sure another shoe will drop in 15 minutes and I will look like a fool.   Won't be the first time.


    SubjectISS & Glass Lewis under scrutiny
    Entry03/19/2019 11:28 AM
    Membermajic06

    Is ISS/Glass Lewis really going to rock the boat on a transaction the size of CELG/BMY while this is going on?  It's one thing if the transaction is clearly value destructive but in this case, it's clearly debatable.  I don't see them rocking the boat right now.  It's not in their self interest.

    https://www.wsj.com/articles/companies-target-firms-that-advise-shareholders-11552987800 

     


    SubjectRe: Author Exit Recommendation
    Entry03/29/2019 06:07 PM
    MemberHarden

    Are you exiting now? Leaving the CVR and easy money on the table? 


    SubjectRe: Re: Author Exit Recommendation
    Entry03/29/2019 06:58 PM
    Membermajic06

    I'm not exiting, fwiw.  Agree the spread here is attractive.  


    SubjectRe: Re: Re: Author Exit Recommendation
    Entry04/05/2019 03:07 PM
    Membermaybeman

    has this has gone from too wide to too narrow?

    ~2.0% ex-CVRs with vote next Friday = done deal and CVRs appreciating?

    Note: ~6.0% assuming BMY's PPA estimate of $3.75 for CVRs

     


    SubjectRe: Re: Re: Re: Author Exit Recommendation
    Entry04/05/2019 03:14 PM
    Membermajic06

    No.  Vote is a done deal and deal is a done deal (I don't think any anti-trust risk).   Assuming 4-5 months to close the IRR is fine here.  BMY has probably bottomed so the best way to play is to be underhedged and long CELG.

    I think CVRs trade $2.50-$3 on day 1, fyi.

      Back to top